Intercell completes acquisition of Pelias
Intercell AG announced that the acquisition of Pelias Biomedical Development AG, Vienna (Austria) was completed with a capital increase. 349.815 new shares, which represent about 0.9 percent of Intercell's current share capital, were issued to the former Pelias shareholders in return for transferring their Pelias shares to Intercell. The 349,815 new shares starttrading at the Vienna Stock Exchange on January 17, 2006. After completion of the capital increase, Intercell's total number of shares issued amounts to 39,881,712.
Pelias will remain a separate legal entity operating as a subsidiary of Intercell AG. Pelias develops products and holds certain licenses in the field of vaccines against important pathogens involved in hospital-acquired infections, including a clinical stage Pseudomonas vaccine candidate and a number of antigens, which have been identified by Intercell's proprietary Antigen Identification Program (AIP®).
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
